| Autor: |
Zhang, Yuxiang, Remillard, David, Onubogu, Ugoma, Karakyriakou, Barbara, Asiaban, Joshua N., Ramos, Anissa R., Bowland, Kirsten, Bishop, Timothy R., Barta, Paige A., Nance, Stephanie, Durbin, Adam D., Ott, Christopher J., Janiszewska, Michalina, Cravatt, Benjamin F., Erb, Michael A. |
| Zdroj: |
Nature Structural and Molecular Biology; 20230101, Issue: Preprints p1-12, 12p |
| Abstrakt: |
Transcriptional co-regulators have been widely pursued as targets for disrupting oncogenic gene regulatory programs. However, many proteins in this target class are universally essential for cell survival, which limits their therapeutic window. Here we unveil a genetic interaction between histone deacetylase 1 (HDAC1) and HDAC2, wherein each paralog is synthetically lethal with hemizygous deletion of the other. This collateral synthetic lethality is caused by recurrent chromosomal deletions that occur in diverse solid and hematological malignancies, including neuroblastoma and multiple myeloma. Using genetic disruption or dTAG-mediated degradation, we show that targeting HDAC2 suppresses the growth of HDAC1-deficient neuroblastoma in vitro and in vivo. Mechanistically, we find that targeted degradation of HDAC2 in these cells prompts the degradation of several members of the nucleosome remodeling and deacetylase (NuRD) complex, leading to diminished chromatin accessibility at HDAC2–NuRD-bound sites of the genome and impaired control of enhancer-associated transcription. Furthermore, we reveal that several of the degraded NuRD complex subunits are dependencies in neuroblastoma and multiple myeloma, providing motivation to develop paralog-selective HDAC1 or HDAC2 degraders that could leverage HDAC1/2 synthetic lethality to target NuRD vulnerabilities. Altogether, we identify HDAC1/2collateral synthetic lethality as a potential therapeutic target and reveal an unexplored mechanism for targeting NuRD-associated cancer dependencies. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink